Clinical Trial: Treatment With Intravitreal Avastin for Large Uveal Melanomas
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Neoadjuvant Treatment With Intravitreal Avastin for Large Uveal Melanomas
Brief Summary: The purpose of this study is to test the safety and effectiveness of Avastin introduced into the inside of the eyeball in causing shrinkage of the uveal melanoma (tumor of the eye). Avastin is an anti-cancer drug specially designed to shrink blood vessels within tumors.
Detailed Summary:
Sponsor: Memorial Sloan Kettering Cancer Center
Current Primary Outcome: The Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). [ Time Frame: At conclusion of study, up to 5 days ]
Original Primary Outcome: To Examine the Response of Intravitreal Avastin in Causing a Clinically Significant Reduction in Uveal Melanoma Tumor Size (Base Height and Volume). [ Time Frame: conclusion of study ]
Current Secondary Outcome:
Original Secondary Outcome: To examine the short-term safety profile of intravitreal injection of Avastin in patients with intraocular tumors. [ Time Frame: conclusion of study ]
Information By: Memorial Sloan Kettering Cancer Center
Dates:
Date Received: January 8, 2008
Date Started: April 2007
Date Completion:
Last Updated: May 16, 2016
Last Verified: May 2016